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with assessing who might benefit from treatments such as
prophylactic G-CSF. METHODS: The literature review
included publications from 1990–2000 of adults with
any tumor type; 121 articles were identified that refer-
enced risk factors or predictors for severe/febrile neutro-
penia. Study design, patient characteristics, chemother-
apy treatment, and incidences of neutropenia were
recorded. RESULTS: Twenty-one relevant publications,
including prospective, retrospective, and modeling stud-
ies, were further analyzed. These articles yielded 27 po-
tential risk factors/predictors in 3 categories: patient (n 
14), treatment-related (n  8), and disease-related (n 
5) characteristics. Although most of the 27 potential risk
factors/predictors were not validated to identify patients
at higher risk for severe/febrile neutropenia, the review
suggests that several simple-to-use and commonly avail-
able risk factors may be reliable predictors of neutrope-
nia. These included low hemoglobin and neutrophil
counts in cycle one; depth of the neutrophil nadir; low
lymphocyte, monocyte and platelet levels; and a precipi-
tous, early drop in blood cell counts. Several other risk
factors, such as serum albumin 3.5g/dL on day 1, se-
rum LDH 1	 normal alone or combined with bone
marrow involvement, and high dose chemotherapy, also
warrant further investigation. CONCLUSIONS: Few
studies have explicitly explored risk factors associated
with the occurrence of Grade 3–4 neutropenia. However,
this literature review identified several common charac-
teristics that may be measured with early and frequent
CBC monitoring and may reasonably predict predisposi-
tion of patients to severe/febrile neutropenia.
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BACKGROUND: In a multinational trial designed to
determine the efficacy of epoetin alfa in chemotherapy-
induced anemia, patients receiving non-platinum chemo-
therapy having a hemoglobin 10.5 g/dL or less, or a decline
in hemoglobin of 1.5 g/dL or greater were randomized
(2:1) to epoetin alfa or placebo. A total of 375 patients
(251 epoetin alfa, 124 placebo) were assessed for survival
status twelve months after completing the protocol, but
prior to unblinding. A log-rank test showed a trend in
survival favoring epoetin alfa (median of 17 vs. 11
months, p  0.128). OBJECTIVES: The primary efficacy
endpoint for many cancer clinical trials is median sur-
vival. In preparing for an economic analysis, however, we
analyzed mean survival, the appropriate survival end-
point for a C/E analysis. METHODS: Sampling with re-
placement, we conducted a post hoc analysis that exam-
ined the difference in mean survival by drawing 10,000
samples in a bootstrapping simulation. Within each sam-
ple the survival curves were truncated to maintain identi-
cal follow-up periods between treatment groups. The dif-
ference in mean survival was computed for each sample.
The probability of superior efficacy was obtained by sort-
ing the results from the samples. RESULTS: The average
mean survival difference, across the 10,000 samples,
showed a 0.212-year survival benefit for epoetin alfa.
The probability that the difference in mean survival fa-
vors epoetin alfa was 0.965. CONCLUSIONS: Compar-
ing differences in median and mean survival may lead to
different conclusions about the value of a therapy. Given
that mean survival is the appropriate effectiveness end-
point for survival-based C/E analyses, a non-significant
difference in median survival does not preclude full C/E
analyses. Specifically, the mean survival results from this
trial warrant a full C/E analysis of epoetin alfa in treating
anemia for patients receiving non-platinum chemotherapy.
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OBJECTIVE: In spite of initial treatment of MBC with DD
showed high level of efficacy expressed as improved dis-
ease-free interval, time to relapse and overall response, it re-
mains as a palliative one. Because of there is some evidence
that QOL is improved with this treatment, we designed the
study to investigate the impact and changes on QOL in pa-
tients (pts) with MBC treated with DD, and its relationship
with clinical parameter of response. Material and METH-
ODS: Between July 1999 and July 2000, we treated 42
MBC pts with doxorrubicin 50mg/m2 and docetaxel 75
mg/m2, i.v., day 1. Inclusion criteria: female between 18–
75 years old, ECOG PS 0-2, and stage IV of MBC histolog-
ically confirmed. QOL was assessed at baseline and prior to
the first, third and fifth cycle of chemotherapy with the
EORTC QLQ-C30 version 2.0, an integrated measurement
system to evaluate QOL of cancer pts. RESULTS: To date,
33 pts (median age  51.7; range 40–67) with available
data, have completed 5 cycles of chemotherapy. Repeated
measures analysis of variance (MANOVA) showed time ef-
fects statistically significant (p  0.5) for Emotional Func-
tioning (EF; p  .001), and Cognitive Functioning (EF; p 
.001) scales, and pain (p  .000), insomnia (p  .05) and
constipation (p  .02) symptom scales. When baseline
QOL was compared with that after 5 cycles (paired t-test),
it was observed significant improved in EF (p  .003), pain
(p  .005) and Insomnia (p  .04). We grouped pts with
CR and PR (n  14) for comparing with SD pts (n  19)
and we observed significantly improve in the first group af-
ter the fifth cycle, in physical functioning (p  .05) and so-
cial functioning (p  .005). CONCLUSION: These prelim-
inary data suggest that pts with MBC undergoing DD
chemotherapy experience improvement in several QOL pa-
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rameters, showing correlation with the clinical response
achieved. There were significant changes in major compo-
nents of QLQ-C30 in pts who achieved clinical response.
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Administrative health care databases are increasingly
used as a source of data for economic studies in cancer.
In order to adjust for disease severity, several investiga-
tors have utilized ICD-9 codes indicating metastases as a
proxy for cancer staging. OBJECTIVE: To determine the
validity of using ICD-9-CM codes indicating metastases
as a proxy to classify lung cancer patients by stage of dis-
ease. METHODS: This retrospective database analysis
used diagnosis codes to classify subjects to either local-
ized or advanced stage disease and then compared this
classification to the tumor registry staging, which was
considered as the “gold standard”. Study subjects in-
cluded all lung cancer patients treated at an academic in-
stitution during 1996–97 who were also members of a
large insurance company. Data was derived from inpa-
tient cancer-related claims linked with the institution’s
tumor registry data. Advanced stage disease (stages II to
IV) was defined by claims indicating lymph node involve-
ment or metastases (ICD-9 codes 196-199.1). The tumor
registry staging of the disease for these patients were clus-
tered into two groupings, stages 0–I (localized) and stages
II–IV (advanced). RESULTS: Tumor registry entries were
identified for 85.7% of patients. The crude concordance
between the claims and tumor registry classifications was
74.2% (Kappa coefficient  0.4848). The positive pre-
dictive value of identifying localized disease utilizing
ICD-9 coding was 57.6%,while the predictive value of a
negative test was 91%. The sensitivity and specificity for
dichotomized disease stage was 86.4% and 68.2% re-
spectively. CONCLUSIONS: For a population of lung
cancer patients in an academic institution, the use of
ICD-9 coding was associated with modest predictability
for disease staging. The use of ICD-9 coding as a proxy
for disease staging in economic evaluations should be ex-
ecuted with caution.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is one of the main treat-
ment options but its availability in the UK is limited in
comparison to other countries, is inconsistent across geo-
graphical regions, with many patients receiving only pal-
liative care. The present study reports results of an eco-
nomic evaluation of Gemzar (one of the newer agents
available) and best supportive care (BSC) relative to BSC
in the treatment of advanced NSCLC. BSC relates to all
forms of care which are non-curative in intent excluding
chemotherapy. METHODS: The study is undertaken
from the perspective of the UK NHS. Data were ex-
tracted from a comparative trial undertaken in the UK
(Anderson et al in 1997). Cost estimates are based on:
chemotherapy and associated infusion, hospitalisations,
health care professional visits, concomitant medications,
radiotherapy and terminal palliative care. Resource utili-
sation data from the clinical trial were combined with
unit-cost data from various UK sources. Costs are pre-
sented in 2000 price levels and the time horizon for their
estimation is one year; hence discounting was unneces-
sary. Treatment effectiveness is measured by progression-
free survival and tumour response. Extensive sensitivity
analysis was also performed. RESULTS: Total treatment
cost per patient in the Gemzar/BSC arm was estimated at
£5,502 and at £3,861 for the BSC arm, the difference at-
tributed mainly to the drug (Gemzar) and its administra-
tion costs. The intervention arm had lower radiotherapy/
concomitant medication costs, but this did not offset the
drug acquisition cost. Progression free life years and
overall tumour response rates were 0.789 and 18.5% in
the Gemzar/BSC arm and 0.474 and 0% in the BSC arm.
The incremental cost-per-progression-free-life-year gained
in Gemzar/BSC relative to BSC is £5,228 and the incre-
mental cost-per-tumour-response £8,873. Changes in the
key variables varied the above ratios between £3,000 and
£23,000. CONCLUSIONS: The economic evaluation
presented above shows that Gemzar/BSC is a cost-effec-
tive therapy for advanced NSCLC relative to BSC alone.
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OBJECTIVES: Pancreatic cancer is a significant and in-
creasing cause of morbidity and mortality in the UK.
Treatment with chemotherapy has shown to improve
symptoms and survival of patients. Gemzar is licenced
for treatment of pancreatic cancer in the UK. This study
reports on an economic evaluation of Gemzar relative to
5-FU, a commonly used regimen for advanced pancreatic
cancer patients in the UK. METHODS: The perspective
is that of the UK-NHS. Data were derived from a clinical
